Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01954251 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 829
- Enrollment target
NCT01954251 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 829 participants.
The verdict
NCT01954251, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 829 participants
- Enrollment target
Study Summary
The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the FLU-D-QIV vaccine in adults aged 50 years or older compared to administration of vaccines separately.
Interventions
- BIOLOGICAL Herpes Zoster vaccine GSK 1437173A
- BIOLOGICAL GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 829 participants |
| Start Date | 2013-10-03 |
| Est. Completion | 2015-03-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01954251
The ClinicalTrials.gov registry entry for NCT01954251 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 829 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Herpes Zoster vaccine GSK 1437173A is the first listed.
NCT01954251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01954251 about?
NCT01954251 is a clinical study titled "Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older". The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the FLU-D-QIV vaccine in adults aged 50 years or older compared to administration of vaccines separately.
What is the current status of trial NCT01954251?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 829 participants. The study started on 2013-10-03. Estimated completion is 2015-03-20.
What interventions are being tested in trial NCT01954251?
The interventions under investigation include: Herpes Zoster vaccine GSK 1437173A (BIOLOGICAL), GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A (BIOLOGICAL).
Who is sponsoring clinical trial NCT01954251?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.